Leonhardt Ventures, CerebraCell & BioLeonhardt File Provisional Patent Application For Electrical Stimulation Controlled Release of IGF-1
Key Tool in Regenerating Brains, Hearts, Eyes, Livers, Kidneys, Breasts, Lungs, Pancreas, Skin, Aortas, Heart Valves, Joints, Limbs and Arteries
Santa Monica, CA and Salt Lake City, Utah , April 1st, 2016 – /PRBuzz- BioLeonhardt MyoStim www.bioleonhardt.com and CerebraCell both founded by Leonhardt Ventures www.leonhardtventures.com a developer, manufacturer and marketer of advanced organ regeneration products has announced the expansion of their intellectual property portfolios. BioLeonhardt MyoStim and CerebraCell are incubating within the Cal-X Stars Business Accelerator, Inc. www.calxstars.com. CerebraCell is dually incuating at the University of Northern California Science and Technology Center (UNC STIC) . The startups via Leonhardt Ventures have filed a provisional patent application with the U.S. Patent and Trademark Office for invention claims relating to bioelectric stimulation controlled release of IGF-1 a powerful cell, tissue and complete organ regeneration growth factor with a special focus on heart and brain regeneration but with applicability to a wide range of other organs and tissues.
Howard J. Leonhardt the Founder and CEO of Leonhardt Ventures, Cerebracell and BioLeonhardt MyoStim and Dr. Jorge Genovese a collaborative researcher from Buenos Aires, Argentina are co-inventors of this product. Howard Leonhardt previously patented a series of electrical stimulation devices and signals for homing stem cells to targeted tissues and the controlled differentiation when required into contractile muscle, even within scar tissue, starting back starting back in 2000. Dr. Genovese has been conducting electrical stimulation based regeneration research for over twenty years with numerous published peer reviewed papers.
“IGF-1 is one of the most potent growth factors in promoting cell, tissue and organ repair applicable to a wide variety of uses. It has been demonstrated to be especially useful in brain regeneration. Some people have referred to IGF-1 as the Fountain of Youth. We are proud to have extended our portfolio of bioelectrical stimulation controlled release of key proteins critical and useful for cell, tissue and organ regeneration to include IGF-1. We believe no other company has come up with a product better able to regenerate organs and tissues than our lineup of bioelectric stimualtors and stem cell micro pumps.” stated Howard J. Leonhardt, Co-Inventor
“Numerous published papers, including a number from our own labs, have documented the powerful ability of IGF-1 to promote repair and regeneration of tissues and organs. Until now there was not a practical, safe and cost effective method of controlled delivery. This invention is designed to solve the missing puzzle piece to reproducibly produce safe results in regenerating not only hearts, brains and limbs but other ailing organs including livers, kidneys, pancreas, eyes, aortas, arteries, heart valves, skin and lungs.” states Dr. Jorge Genovese co-inventor
IGF-1 can instigate the delivery of RNA, DNA and nucleic acids directly into a cell nucleus. Meanwhile nucleic acids are helpful in repairing the damage in the DNA, while stimulating cell division. Insulin-like Growth Factor-1 was demonstrated in pre-clinical studies to be a Potent Neuronal Rescue Agent after Hypoxic-Ischemic Injury in Fetal Lambs http://dm5migu4zj3pb.cloudfront.net/manuscripts/118000/118416/JCI96118416.pdf
Howard Leonhardt co-inventor of this device previously patented an electrical stimulation device for recruiting stem cells to damaged organs including the heart by causing the release of SDF-1 stromal derived factor-1 on demand working in collaboration with Dr. Juan Chachques of Paris – http://www.google.com/patents/US20050171578. This issued U.S. patent has a separate claim for controlling the differentiation of pluripotent stem cells , recruited or injected from sources of bone marrow, fat and circulating blood, to contractile muscle in the depth of myocardial scar tissue. The stimulation voltages of this Leonhardt Chachques patented device range from 1 mV to about 40 mV in line with natural voltages sent by the brain to tissues to stimulate protein releases for repair and regeneration naturally. Also following natural signals utilized to form heart tissue during fetal development. In total Howard Leonhardt co-inventor of this provisional patent has over 21 issued U.S. patents related to treating heart and cardiovascular disease with over 100 individual patent claims with dozens more pending or in process – http://patents.justia.com/inventor/howard-j-leonhardt The Leonhardt Ventures led team has developed bioelectric signaling for the controlled release of SDF-1, VEGF, VEGF-B, Anti-VEGF, HGF, Follistatin, RANKL, Tropinelastin and now IGF-1 and is working on dozens of others.
Howard Leonhardt presented earlier this year their team’s 27 Year Experience with Stem Cell Therapies for Organ Regeneration and highlighted some of the spin out startup techonlogy platforms that have emerged from the original work on heart regeneration which are now also incubating in the Cal-X Stars Business Accelerator, UNC STIC and Leonhardt’s Launchpads – https://mysocialgoodnews.com/howard-leonhardt-to-present-27-years-of-experience-with-stem-cell-therapies-at-academy-of-regenerative-practices-winter-conference-and-scientific-seminar/
About BioLeonhardt MyoStim:
BioLeonhardt MyoStim is a developer of products for heart and limb regeneration. Its flagship product for heart regeneration utilizes a micro voltage signal generator the size of a quarter implanted in the abdomen of a patient coupled with a re-fillable micro pump. The regeneration stimulator is programmed to cause stimulated tissues to release on demand control SDF-1 (a stem cell homing signal), VEGF (a blood vessel growth protein), HGF (an arrhythmia inhibitor), Follistatin (a muscle repair and formation promotor), VEGF microRNA PI3K/Ak activity enhancer for cardiac stem cell migration, Tropinelastin (improves elasticity of tissues). The micropump is re-filled at least once a week with MicroRNAs, nutrient hydrogel, adipose derived cells including endothelial progenitor cells, muscle stem cells, follistatin, pyruvate, tropinelastin, cardiac matrix and a cardiomyogenic and angiogenic cocktail of additional growth factors. The pump+stimulator combination is designed to totally regenerate a failing heart over a 36 month course of treatment. A similar combination product is used for limb salvage. BioLeonhardt MyoStim legally operates now during its formative development stage as a technology platform license unit (startup) of Leonhardt Vineyards LLC DBA Leonhardt Ventures operating within the Cal-X Stars Business Accelerator, Inc. and will soon be spun out as a stand alone C corporation when its own financial standing is secure enough. All capital for BioLeonhardt MyoStim and other Cal-X Stars Business Accelerator, Inc. incubating startups and licensable technology platforms (all very high risk early stage startups – undercapitalized and understaffed) is raised only through Cal-X Stars Business Accelerator, Inc via 506D Part C – SEE RISK FACTORS HERE > http://calxstars.com/investor-relations/ limited to accredited and sophisticated investors only or Leonhardt Ventures’s own internal funds at this time. Leonhardt Ventures’ Cal-X Stars Business Accelerator is led by over 70 business mentors and team members with substantial industry experience – http://calxstars.com/team-cal-x/ and over 35 scientists and clinicians on our Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/
About Leonhardt Ventures:
Since 1982 Howard Leonhardt (later registered as Leonhardt Vineyards LLC DBA Leonhardt Ventures 2005) www.leonhardtventures.com has led the development and marketing of devices and biologics for treating cardiovascular and heart disease. In the 1980s they developed leadership in patented cardiovascular compliant balloon catheters, in the 1990’s stent grafts and percutaneous heart valves, in the 2000’s stem cell compositions for heart muscle repair and 2010’s electrical stimulation regenerative devices – Leonhardt Ventures owns 50.1% of Cal-X Stars Business Accelerator, Inc. formed in 2012 and incorporated in California in 2013 a 5 year business and innovation accelerator for regenerative medtech and regenerative ecnonomy startups www.calxstars.com The above mentioned startups are all startup technology platforms at this time within the accelerator transitioning over 5 years from early stage concepts into full fledged stand alone companies. Cal-X Stars also helps operate Leonhardt’s Launchpads www.leonhardtslaunchpads.com and the newly formed Leonhardt’s Launchpads Utah, LABioHub www.labiohub.org, Startup California http://startupcalifornia.org, Cal-X Crowdfund Connect www.calxcrowdfund.com and Cal-Xelerator www.calxelerator.com all focused on launching early stage startups.
About CerebraCell:
CerebraCell – microcurrent based non-invasive or minimally invasive energy system for brain regeneration which for advanced cases may be coupled with a stem cell/growth factor micro pump. Also non-invasive cerebral aneurysm repair –
About EyeCell:
EyeCell (eye) – – is focused on bioelectric stimulation and stem cell micro pump regeneration of failing eyes.
This provisional patent application was filed electronically utilizing www.legalzoom.com software.
Source:
